Studying Costs and Quality of Life With Early or Delayed Leukemia Treatment
Follows adults with early chronic lymphocytic leukemia on health care use and daily life.
Plain-language title generated from the registry record
Registry title: Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Key facts
- Where
- Montreal, Oshawa, Ottawa, Saint John, Vancouver, and Winnipeg, CanadaSee the 6 sites
Where in Canada
- The Jewish General HospitalMontreal, CanadaTaking people
- Lakeridge Health OshawaOshawa, CanadaNot yet recruiting
- Ottawa Hospital Research InstituteOttawa, CanadaNo longer taking part
- Regional Health Authority B, Zone 2Saint John, CanadaTaking people
- BCCA - VancouverVancouver, CanadaTaking people
- CancerCare ManitobaWinnipeg, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Canadian Cancer Trials Group
- Trial code
- NCT05371808
- Record updated
- 14 October 2026
- Original description
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or completion of 10 years of follow-up.Read full original descriptionShow less
An Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3/SWOG 1925 Randomized Phase III Clinical Trial
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or completion of 10 years of follow-up.
Protocol-specified health care utilization will be collected within trial case report forms, and will include study visits, radiographic assessments, laboratory investigations, and treatment administration.
Resource utilization data collection will be supplemented by a self-administered resource utilization form (Stanford SMRC) to document non-protocol specified utilization. This will include hospitalizations (including days in hospital), emergency room visits, and non-protocol specified ambulatory visits.
Inclusion: Patient must be eligible for the core CLC3/S1925 protocol; Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate; Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to enrollment. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible; Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.